Develops cell-based immunotherapies for patients with breast and other cancers, targeting oncologists and cancer treatment centers.
10-K for FY2026, filed Oct 28, 2026BriaCell Therapeutics Corp. (“Briacell” or the “Company”) is a clinical-stage biotechnology company that is developing novel…View ↗
BriaCell Phase 1/2 Study of Bria-OTS™, the Company’s personalized off-the-shelf immunotherapy, in metastatic breast cancer is ongoing…View ↗
BriaCell is currently developing Bria-OTS™ and its advanced form, Bria-OTS+™, as a platform technology for personalized off-the-shelf…View ↗
Marketing will target oncologists who are well-versed in the use of immunotherapy and especially breast cancer treatment centers. The…View ↗
No revenue reported yet.
10-K for FY2026, filed Oct 28, 2026
Plans to reach oncologists, especially breast cancer treatment centers, through physician education; partnering with established pharmaceutical companies is also an option.
10-K for FY2026, filed Oct 28, 2026Marketing will target oncologists who are well-versed in the use of immunotherapy and especially breast cancer treatment centers. The…View ↗
Competes with Marker Therapeutics, Antigen Express, Merck, Bristol-Myers Squibb, Merck &, Genentech, AstraZeneca, Celgene, Johnson & Johnson, Janssen Pharmaceuticals, Amgen, Novartis, Acerta Pharmaceuticals, Juno Therapeutics, Kite Pharma, Gilead Sciences, Pfizer, and EMD Serono
10-K for FY2026, filed Oct 28, 2026There are cancer vaccines in development for breast cancer, including but not limited to TPIV200 (Marker Therapeutics, Inc.), AE-37…View ↗
Loading...